Saniona AB
STO:SANION
Saniona AB
Operating Income
Saniona AB
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Saniona AB
STO:SANION
|
Operating Income
-kr67m
|
CAGR 3-Years
47%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr7.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
22%
|
CAGR 10-Years
39%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
-kr1.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-33%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€278.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-37%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Operating Income
-kr69.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-15%
|
|
Saniona AB
Glance View
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
See Also
What is Saniona AB's Operating Income?
Operating Income
-67m
SEK
Based on the financial report for Sep 30, 2024, Saniona AB's Operating Income amounts to -67m SEK.
What is Saniona AB's Operating Income growth rate?
Operating Income CAGR 5Y
9%
Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Saniona AB have been 47% over the past three years , 9% over the past five years .
You don't have any saved screeners yet